MT Newswires on MSN
AlphaTON Capital, Subsidiary Tarus Therapeutics Explore Tokenization of Mesothelioma Drug TT-4 Economics
AlphaTON Capital (ATON) said Wednesday together with its oncology unit Tarus Therapeutics they have signed a non-binding letter of intent to explore tokenization of economics for mesothelioma program ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results